MYND Life Sciences Inc. (MYNDF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMYND Life Sciences Inc. (MYNDF) trades at $0.0081. MYND Life Sciences Inc. is a neuro-pharmaceutical drug development company focused on creating medicines for depressive disorders. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for MYNDF: MYNDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
MYND Life Sciences Inc. (MYNDF) Healthcare & Pipeline Overview
MYND Life Sciences Inc. is a biotechnology company specializing in the development of neuro-pharmaceutical drugs targeting depressive disorders. Operating in the healthcare sector, the company focuses on research and clinical trials involving psilocin and psilocybin analogs within Canada and the United States, positioning itself in the evolving field of neuro-anti-inflammatory treatments.
What Is the Investment Thesis for MYNDF?
MYND Life Sciences Inc. presents a speculative investment opportunity within the burgeoning field of psychedelic-based therapeutics. The company's focus on psilocin and psilocybin analogs for depressive disorders positions it within a high-growth area of the biotechnology sector. A key value driver is the successful completion of clinical trials and subsequent regulatory approvals in Canada and the United States. Upcoming catalysts include the progression of drug candidates through clinical trial phases and potential partnerships with larger pharmaceutical companies. However, potential risks include regulatory hurdles, competition from other companies in the psychedelic medicine space, and the inherent uncertainty associated with drug development. The company's current P/E ratio of -2.18 reflects its pre-revenue status and reliance on future clinical and commercial success.
Based on FMP financials and quantitative analysis
MYNDF Key Highlights
MYND Life Sciences Inc. operates in the biotechnology industry, focusing on neuro-pharmaceutical drug development.
- The company specializes in medicines based on neuro-anti-inflammatory substances for depressive disorders.
- MYND Life Sciences Inc. conducts science and clinical trials in Canada and the United States.
- The company focuses on the analysis of psilocin and psilocybin extracts and analogs.
- MYND Life Sciences Inc. has a P/E ratio of -2.18, reflecting its current earnings status.
Who Are MYNDF's Competitors?
MYNDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $37.32 | -0.21% | $166B | 91 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $504.73 | -0.40% | $128B | 97 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $735.20 | +0.05% | $75.7B | 94 5-pillar |
| ARGX argenx SE | $919.21 | -1.79% | $57.2B | 97 5-pillar |
| ALNY Alnylam Pharmaceuticals, Inc. | $219.72 | -4.96% | $29.4B | 89 5-pillar |
| RPRX Royalty Pharma plc | $57.16 | -0.82% | $25.3B | 74 5-pillar |
| INCY Incyte Corporation | $115.30 | -1.57% | $23.4B | 98 5-pillar |
| UTHR United Therapeutics Corporation | $541.70 | -5.19% | $23.0B | 97 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MYNDF's Key Strengths?
Focus on innovative neuro-pharmaceutical drugs.
- Expertise in psilocin and psilocybin analogs.
- Established research and clinical trial infrastructure.
- Strategic partnerships with key stakeholders.
What Are MYNDF's Weaknesses?
Limited financial resources.
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Limited commercialization experience.
What Are the Key Risks for MYNDF?
Financial-distress signal — its Altman Z-Score of -36.44 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and changing regulations.
- Competition from established pharmaceutical companies.
- Uncertainty surrounding clinical trial outcomes.
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
What Are MYNDF's Competitive Advantages?
- Intellectual property protection through patents.
- Specialized expertise in neuro-anti-inflammatory substances.
- Established research and clinical trial infrastructure.
- Strategic partnerships with key stakeholders.
What Does MYNDF Do?
MYND Life Sciences Inc. is a life sciences company dedicated to the research and development of neuro-pharmaceutical drugs, specifically targeting depressive disorders. The company operates in Canada and the United States, focusing on advancing medicines through scientific research and clinical trials. MYND Life Sciences specializes in the analysis of psilocin and psilocybin extracts and analogs, exploring their potential therapeutic applications. The company's core mission is to develop innovative treatments for mental health conditions by leveraging neuro-anti-inflammatory substances. MYND Life Sciences is committed to rigorous scientific investigation and clinical validation to bring novel therapies to market. Headquartered in Kelowna, Canada, the company is strategically positioned to capitalize on the growing interest and investment in psychedelic-based medicines for mental health. MYND Life Sciences aims to address the unmet needs in the treatment of depressive disorders by developing pharmaceuticals that offer improved efficacy and reduced side effects compared to existing treatments. The company's focus on neuro-anti-inflammatory substances represents a novel approach to mental health treatment, potentially offering new hope for patients suffering from these conditions.
What Products and Services Does MYNDF Offer?
- Develop neuro-pharmaceutical drugs for depressive disorders.
- Conduct scientific research and clinical trials in Canada and the United States.
- Focus on medicines based on neuro-anti-inflammatory substances.
- Analyze psilocin and psilocybin extracts and analogs.
- Seek regulatory approvals for their drug candidates.
- Explore strategic partnerships with pharmaceutical companies.
- Develop novel analogs of psilocin and psilocybin.
How Does MYNDF Make Money?
- Research and development of neuro-pharmaceutical drugs.
- Conducting clinical trials to demonstrate safety and efficacy.
- Seeking regulatory approvals for commercialization.
- Potential revenue generation through drug sales and licensing agreements.
What Industry Does MYNDF Operate In?
MYND Life Sciences Inc. operates within the biotechnology industry, specifically targeting the emerging market for psychedelic-assisted therapies. The industry is experiencing increased interest and investment due to the potential of these substances to treat mental health disorders such as depression and anxiety. This market is characterized by intense competition and evolving regulatory landscapes. MYND Life Sciences aims to differentiate itself through rigorous scientific research and clinical trials, positioning itself to capitalize on the growing demand for innovative mental health treatments.
Who Are MYNDF's Key Customers?
- Patients suffering from depressive disorders.
- Healthcare providers prescribing mental health treatments.
- Pharmaceutical companies seeking to expand their product portfolios.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
MYND Life Sciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Port Coquitlam, CA. The company is led by CEO Wilfred A. Jefferies. MYNDF has traded publicly since 2021.
Key Financial Metrics
Return on equity for MYND Life Sciences Inc. stands at 35.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.14 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -45.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
MYND Life Sciences Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -36.44 places it in the distress zone, a signal of elevated financial risk.
MYNDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
MYNDF Latest News
No recent news available for MYNDF.
MYNDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MYNDF.
Price Targets
Wall Street price target analysis for MYNDF.
MYNDF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MYNDF; grades run from A+ (80-100) to F (below 30).
Leadership: Wilfred A. Jefferies
CEO
Wilfred A. Jefferies is the CEO of MYND Life Sciences Inc. His background includes extensive experience in the life sciences industry, with a focus on pharmaceutical development and commercialization. He has held leadership positions in various biotechnology companies, overseeing research and development, clinical trials, and regulatory affairs. Jefferies has a proven track record of driving innovation and building successful teams. His expertise in neuro-pharmaceuticals makes him well-suited to lead MYND Life Sciences in its mission to develop novel treatments for depressive disorders.
Track Record: Under Wilfred A. Jefferies' leadership, MYND Life Sciences Inc. has focused on advancing its pipeline of neuro-pharmaceutical drug candidates through preclinical and clinical development. He has overseen the expansion of the company's research and development efforts, focusing on the analysis of psilocin and psilocybin extracts and analogs. Jefferies has also been instrumental in securing strategic partnerships and funding to support the company's growth initiatives.
MYNDF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MYND Life Sciences Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity and transparency.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of transparency due to less stringent disclosure requirements.
- Potential for price volatility.
- Higher risk of fraud or manipulation.
- Limited access to company information.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's regulatory filings and compliance history.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Company is actively engaged in research and development.
- Company has secured patents for its drug candidates.
- Company has established partnerships with reputable organizations.
- Company has a clear business plan and strategy.
- Company is transparent about its operations and financials (to the extent available).
MYNDF Healthcare Stock FAQ
What do analysts say about MYNDF stock?
As of 2026-03-18, there is no readily available analyst consensus on MYNDF stock due to its OTC listing and limited coverage.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.